| Name | Title | Contact Details |
|---|
Agenixs creates change in the world by elevating people to healthier, longer, and more fulfilling lives, empowering each on their own journey of changing the world.
CODAC Behavioral Health Services of Pima County is a nonprofit 501(c)(3) organization that provides mental health and substance use disorder treatment and prevention programs to children, adults and families in Pima County. It is CODAC’s mission to work collaboratively with individuals, families and organizations to eliminate the harmful effects of substance use disorders, mental illness and abuse on their lives and families. CODAC was founded in 1970 and has evolved into a comprehensive service provider with a full continuum of mental health and substance use disorder treatment programs for youth (ages 12-17), young adults (ages 18-21) and adults (ages 22+) and their families at 10 conveniently located sites. CODAC’s prevention services are community-based and recognized as best-practices for preventing risky behaviors in Pima County youth and families.
At Footprints to Recovery, our mission is to transform your life of addiction to a life of hope through inspiration, education, and support. We`re an individual focused and evidenced based addiction rehabilitation center, that emphasizes meaningful connections in recovery. We are conveniently located in Hamilton, NJ and Arlington Heights, IL.
Alnylam is the world`s leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today`s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn`t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That`s why we`ve been named a Science Magazine Top Employer for two years in a row (`19-`20), a Boston Globe Top Place to Work 5x in a row (`15-`19) and one of Fast Company`s 50 Most Innovative Companies for 2019. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America.